GlassScriptPhysician profile
Rebekah E Garrard
NPI 1952656027
$104,928.67
in general payments reported to CMS, 2019-2025
59 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,083 · 2022: $21K · 2023: $12K · 2024: $29K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Consulting Fee: $19K · Food and Beverage: $16K · Travel and Lodging: $13K · Education: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,649.00 |
| Consulting Fee | $19,417.50 |
| Food and Beverage | $15,839.45 |
| Travel and Lodging | $13,327.00 |
| Education | $443.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $32,490.07 | 2021-2025 | Tremfya, Simponi Aria |
| Janssen Scientific Affairs, LLC | $18,043.78 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $17,872.85 | 2021-2025 | Taltz, Olumiant, Jardiance |
| Novartis Pharmaceuticals Corporation | $12,185.60 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $6,039.06 | 2021-2025 | Orencia, Sotyktu |
| Amgen INC. | $5,290.79 | 2021-2025 | Otezla, Enbrel, Tavneos |
| Abbvie INC. | $2,732.69 | 2021-2025 | |
| Eli Lilly and Company | $1,500.00 | 2024 | Taltz |
| Ucb, INC. | $1,067.05 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $925.31 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $659.39 | 2021-2025 | Strensiq |
| Aurinia Pharma U.S., INC. | $568.24 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $494.98 | 2023-2025 | Ofev, Spevigo, Jardiance |
| Radius Health, INC. | $484.50 | 2021-2025 | Tymlos |
| Glaxosmithkline, LLC. | $338.05 | 2021-2025 | Benlysta |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $314.81 | 2024-2025 | Crysvita |
| Ani Pharmaceuticals, INC. | $301.53 | 2022-2025 | Purified Cortrophin Gel |
| Sobi, INC | $283.09 | 2022-2025 | |
| Corcept Therapeutics | $259.75 | 2021-2025 | Korlym |
| Genentech USA, INC. | $241.84 | 2021-2023 | Actemra |
| Fresenius Kabi USA, LLC | $241.33 | 2023-2024 | Idacio |
| Mallinckrodt Hospital Products INC. | $226.32 | 2021-2025 | Acthar |
| Horizon Therapeutics Plc | $203.53 | 2021-2023 | Krystexxa |
| Beta Bionics, INC. | $200.92 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Pfizer INC. | $176.27 | 2022-2025 | |
| Insulet Corporation | $170.69 | 2023-2025 | Omnipod |
| Recordati_rare_diseases_inc. | $168.96 | 2024-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $147.26 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $130.27 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $109.55 | 2022-2023 | Steglujan, Steglatro, Segluromet |
| Sanofi-Aventis U.S. LLC | $102.06 | 2021-2025 | |
| Medtronic, INC. | $93.11 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Antares Pharma, INC. | $86.53 | 2021 | |
| Novo Nordisk INC | $86.02 | 2021-2025 | Ozempic |
| Boston Scientific Corporation | $71.69 | 2021 | |
| Chiesi USA, INC. | $61.83 | 2024-2025 | Mycapssa |
| Sandoz INC. | $53.72 | 2023-2025 | Hyrimoz |
| Neurocrine Biosciences, INC. | $44.29 | 2025 | |
| Madrigal Pharmaceuticals | $42.70 | 2025 | Rezdiffra |
| Organon LLC | $41.26 | 2025 | Renflexis |
| Amarin Pharma, INC. | $40.58 | 2021-2022 | |
| Clarus Therapeutics INC. | $35.54 | 2021 | |
| Amryt Pharma Holdings LTD | $25.24 | 2023 | Mycapssa |
| Teva Pharmaceuticals USA, INC. | $22.44 | 2024 | Truxima |
| Takeda Pharmaceuticals U.S.A., INC. | $22.10 | 2021 | |
| Abbott Laboratories | $21.72 | 2025 | Freestyle Libre 3 |
| Celltrion USA INC. | $19.97 | 2023 | Yuflyma |
| Sequel Med Tech, LLC | $18.84 | 2025 | Twiist |
| Acella Pharmaceuticals, LLC | $18.25 | 2023 | NP Thyroid 60 |
| Tandem Diabetes Care, INC. | $17.83 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Becton, Dickinson and Company | $17.53 | 2022 | |
| Ascendis Pharma Endocrinology INC | $17.39 | 2023 | |
| Zealand Pharma US, INC. | $16.90 | 2021 | |
| Cequr Corporation | $16.58 | 2025 | Cequr Simplicity |
| Ultragenyx Pharmaceutical INC. | $15.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.87 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $13.04 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $12.93 | 2023 | Arcalyst |
| Vivus LLC | $9.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebekah Garrard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.